Endoscopic banding combined with intrabulbar sclerosis ligation was used in a clinical research to treat esophagogastric variceal bleeding in liver cirrhosis and portal hypertension

Status

Recruiting

Phases

Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2500108351

Enrollment

Unknown

Registered

2025-08-28

Start date

2024-08-20

Completion date

Unknown

Last updated

2025-09-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Esophagogastric Variceal Bleeding Secondary to Cirrhotic Portal Hypertension

Interventions

The control group:The control group underwent conventional endoscopic variceal ligation (EVL) under intravenous anesthesia. A standard gastroscopy was performed to evaluate the extent and severity of

The observation group :The observation group received combined endoscopic variceal ligation (EVL) with sclerotherapy based on the control protocol. Using the ligation-induced variceal bulbs as sclerot

Eligibility

Sex/Gender

All

Age

18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. History of liver cirrhosis with clinical manifestations of digestive tract bleeding (hematemesis or melena); 2. Diagnosed as EVB through endoscopy; 3. No history of endoscopic, surgical, or interventional treatments; 4. Has not used ß-blockers such as atenolol, metoprolol, and nitrate drugs such as nitroglycerin, isosorbide dinitrate, etc.; 5. Meets relevant surgical standards; 6. Aged 18 years or older, with the ability to understand independently, and voluntarily signing the informed consent for endoscopic treatment; 7. High patient compliance, able to follow up on time; 8. Complete clinical data.

Exclusion criteria

Exclusion criteria: 1. Patients for whom endoscopic intervention is contraindicated. 2. Patients with severe concomitant organ dysfunction. 3. Coagulopathy of non-hepatic origin. 4. Patients with psychiatric disorders or significant cognitive or communication impairment. 5. Pregnant or lactating women, or women planning to become pregnant during the study period. 6. Patients aged = 70 years. 7. Patients with portal vein thrombosis or tumor thrombus. 8. Patients with incomplete clinical data.

Design outcomes

Primary

Measure	Time frame
Rebleeding rate;Success rate of hemostasis;	—

Secondary

Measure	Time frame
Rate of improvement in esophagogastric varices;Postoperative complications;All-cause mortality;	—

Countries

China

Contacts

Public ContactYang Lei

China-Japan Union Hospital of Jilin University

1712458480@qq.com+86 137 5669 8212

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026